[R&D] SPLICER: a highly efficient base editing toolbox that enables in vivo therapeutic exon skipping

[R&D] Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE

식약처, 유전자가위 치료제 개발 지원방안 모색

‘글로벌 전문가 자문단’ 출범, 첨단 의료제품 개발 가속화

[R&D] Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases

[Market] 유전자가위 관련 법·제도, 연구개발, 사회경제 동향

[R&D] 후성유전학의 최신 동향과 응용

[R&D] 유전자 교정 기술의 발전과 활용

[Market] 유전자세포치료제(GCT) 비용 절감을 위한 모델

[R&D] Effective genome editing with an enhanced ISDra2 TnpB system and deep learning-predicted ωRNAs

[R&D] Highly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation

[Market] 식약처, 혈우병 치료 유전자치료제 국내 최초 허가

[R&D] Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study

[R&D] Structural basis of Cas3 activation in type I-C CRISPR-Cas system

[R&D] 세포·유전자치료제(CGT) 개발 동향